Does UnitedHealthcare Cover Weight Loss Drugs? OptumRx Coverage Review

Short version: UnitedHealthcare is the largest commercial health insurer in the United States, and it runs its prescriptions through its own pharmacy benefit manager, Optum Rx. GLP-1s for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Rybelsus, and generic liraglutide) sit on UHC’s 2026 commercial Prescription Drug List with prior authorization. GLP-1s for chronic weight management (Wegovy, Zepbound, Foundayo, Saxenda) are a different story: UHC’s own drug list says weight-loss medications are excluded from coverage under most benefit plans, and its weight-loss prior-authorization program applies only to employers and plans that have elected to cover them. About three in four UHC commercial members are in fee-based (self-funded) employer plans, where the employer makes that call. UHC Medicare Advantage members face the federal Part D weight-loss exclusion, but since July 1, 2026 they can use the CMS-run Medicare GLP-1 Bridge ($50 a month) if they qualify. UHC Community Plan (Medicaid) defers to each state. Because UHC runs its drug list through its PBM, see also our guide on does OptumRx cover weight-loss drugs.

At a glance

• UHC GLP-1 coverage for type 2 diabetes: generally YES with PA. Ozempic, Mounjaro, Trulicity, and Rybelsus are Tier 2 with prior authorization and quantity limits on UHC’s commercial Prescription Drug List effective September 1, 2026; generic liraglutide (Victoza) is also listed with PA.^[1]
• UHC GLP-1 coverage for chronic weight management: CONDITIONAL, and usually NO. UHC’s drug list states that weight-loss medications are excluded under most benefit plans.^[2] Its weight-loss PA program (Wegovy injection, Wegovy HD, Zepbound, Foundayo, Saxenda, Qsymia, Contrave, phentermine and others) is “an optional program” for clients that elect to cover these drugs.^[3]
• The self-funded reality: at September 30, 2026, 22.2 million of UHC’s 29.8 million commercial members (about 75%) were in fee-based arrangements, where the employer, not UHC, decides whether to cover weight-loss drugs.^[5]
• Wegovy tablets and brand Saxenda: UHC says Wegovy tablets are typically excluded from coverage, and from January 1, 2027 its commercial Advantage 3-Tier PDL excludes Wegovy tablets and brand-only Saxenda, pointing to Wegovy injection, Zepbound, Qsymia, or generic liraglutide instead.^[2][3]
• UHC Medicare Advantage (Part D): NO for weight-loss-only Wegovy/Zepbound/Saxenda — federal law excludes “agents when used for anorexia, weight loss, or weight gain” from Part D.^[7] Coverable for Zepbound’s sleep-apnea indication and Wegovy’s cardiovascular and MASH indications.^[10][11]
• Medicare GLP-1 Bridge (since July 1, 2026): eligible Part D members, including UHC Medicare Advantage members, can get Wegovy (injection or tablet), Zepbound KwikPen, or Foundayo for weight loss at a $50 monthly copay through December 31, 2027, through a CMS program that runs outside the UHC plan.^[8][9]
• UHC Community Plan (Medicaid managed care): follows each state’s Medicaid preferred drug list. Some state contracts cover weight-loss GLP-1s; others exclude them.
• Automated PA: Optum Rx’s PreCheck Prior Authorization, launched with Surescripts in October 2024, can auto-approve select drugs, including GLP-1s for diabetes, at participating health systems, with a reported median of 29 seconds.^[6]

How UnitedHealthcare actually decides — Optum Rx + your employer's plan design

UnitedHealthcare, unlike an integrated HMO such as Kaiser Permanente, is a PBM-administered insurer. Prescriptions are adjudicated by its in-house pharmacy benefit manager, Optum Rx, which administers the drug list, tiers, and prior authorization. Members fill at retail pharmacies or via Optum Rx mail order, and claims route back to Optum Rx.

But there is a second, decisive layer that catches most members off guard: the employer’s benefit design. UnitedHealthcare reports two structurally different kinds of commercial business:

• Risk-based (fully insured) plans — UHC bears the claims risk. About 7.6 million commercial members at September 30, 2026.^[5] Weight-loss drug coverage still depends on whether the employer group bought it, plus any state mandate that applies.^[3]
• Fee-based (self-funded / ASO) plans — the employer bears the claims risk and UHC/Optum Rx administers the benefit. About 22.2 million commercial members.^[5] Here the employer chooses what the pharmacy benefit covers, including whether anti-obesity medications are in or out.

Two practical implications for weight-loss-drug coverage:

1. For type 2 diabetes, the drug list is the gatekeeper. T2D GLP-1s are on the commercial drug list with PA; the only questions are the PA criteria and your tier.
2. For weight loss, the employer’s election is the gatekeeper. If your employer did not elect AOM coverage, Wegovy, Zepbound, Foundayo, and Saxenda are simply not a covered benefit for weight loss. No amount of BMI documentation or comorbidity evidence overrides a benefit exclusion — that is a contract limitation, not a clinical PA denial. This is the single most common reason a UHC member is “denied” a weight-loss GLP-1.

GLP-1 coverage for type 2 diabetes (broadly covered)

On UHC’s commercial Prescription Drug List (effective September 1, 2026), GLP-1 receptor agonists for type 2 diabetes are listed with prior authorization and quantity limits.^[1] The agents covered:

• Ozempic (semaglutide) — once-weekly injection; Tier 2 with PA + QL.^[1] FDA-approved for T2D and for CV risk reduction in T2D with established CVD.
• Mounjaro (tirzepatide) — once-weekly dual GIP/GLP-1; Tier 2 with PA + QL.^[1] Its label now also covers reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for these events, and T2D in children 10 and older.^[12] See our tirzepatide drug page.
• Trulicity (dulaglutide) — once-weekly GLP-1; Tier 2 with PA + QL.^[1] FDA-approved for T2D and CV risk reduction.
• Rybelsus (oral semaglutide) — daily oral tablet; Tier 2 with PA + QL.^[1] See our semaglutide drug page.
• Liraglutide (generic Victoza) — daily GLP-1 for T2D; listed generically with PA and quantity limits.^[1]

Typical PA criteria for a T2D GLP-1 include a confirmed T2D diagnosis (ICD-10 E11.x), a documented A1C, often a metformin trial or documented intolerance, and prescriber documentation of treatment goals. Exact criteria are plan-specific; the prescriber submits the PA through the Optum Rx or UHC provider portal.

GLP-1 coverage for chronic weight management (only if your plan elected it)

This is where UnitedHealthcare becomes complicated. The FDA-approved weight-management GLP-1s — Wegovy (semaglutide injection, including the 7.2 mg Wegovy HD dose, and Wegovy tablets), Zepbound (tirzepatide), Foundayo (orforglipron, a once-daily oral GLP-1 approved in 2026), and Saxenda (liraglutide 3.0 mg) — are covered with PA on plans that elected weight-loss coverage, and not covered for weight loss on plans that did not.^{[3][10][11][13]}

UHC’s current weight-loss PA program (program 2026 P 1114-23, effective October 1, 2026) sets these initial criteria:^[3]

• BMI ≥ 30 kg/m² (or above the 95th percentile for children), OR BMI ≥ 27 kg/m² with a weight-related comorbidity such as dyslipidemia, hypertension, type 2 diabetes, or sleep apnea. No BMI threshold applies when Wegovy injection is requested for MASH.
• Age 12 or older for Wegovy injection, Saxenda, Qsymia, and Xenical; older than 16 for the other listed drugs, including Zepbound and Foundayo.
• Use as an adjunct to lifestyle modification (diet or caloric restriction, exercise, behavioral support, or a community-based program). The criteria do not require trying one GLP-1 before another, though individual plans can still add step therapy.^[2]
• Initial authorization lasts 5 months for Wegovy and 6 months for Zepbound and Foundayo. Reauthorization runs 12 months and, for Wegovy, requires at least 5% weight loss from baseline; patients still titrating at the end of the first authorization can get one additional 6-month approval.

The same document allows the Wegovy request for cardiovascular risk reduction or MASH, and the Zepbound request for moderate-to-severe obstructive sleep apnea, and refers plans that do not cover weight-loss drugs to separate “nonformulary” Wegovy and Zepbound criteria for those indications.^[3] In other words, a weight-loss exclusion does not automatically block the CV, MASH, or OSA uses. For drug-level reference data, see our semaglutide and tirzepatide drug pages.

Benefit exclusion vs PA denial — they are not the same thing

This distinction matters enormously for what you can do about a “no.”

• A PA denial means the drug class IS covered by your plan but you have not met (or have not documented) the clinical criteria. This is appealable on clinical grounds — resubmit with the missing BMI, comorbidity, or lifestyle documentation, then escalate.
• A benefit exclusion means your employer did not elect AOM coverage, so weight-loss drugs are not part of your pharmacy benefit at all. A clinical appeal will not reverse this, because there is no clinical question — it is a contract term. The realistic levers are: ask HR/benefits whether AOM coverage can be added at renewal, pursue a covered non-weight-loss indication (OSA, CV risk, MASH), or use a self-pay pathway.

Always confirm which one you are facing before spending effort on an appeal. Your plan’s Summary Plan Description (SPD) or Evidence of Coverage (EOC) lists AOM exclusions explicitly in the excluded-benefits section.

UHC Medicare Advantage (Part D) — federal exclusion

UnitedHealthcare is one of the largest Medicare Advantage carriers in the country, with about 7.6 million MA members at September 30, 2026.^[5] Like every Medicare Part D plan, UHC MA-PD plans operate under Social Security Act §1860D-2(e)(2)(A), which carries over the Medicaid list of excludable drugs, including “agents when used for anorexia, weight loss, or weight gain.”^[7] This is a federal statutory exclusion — a UHC Medicare Advantage plan cannot cover Wegovy, Zepbound, or Saxenda for weight loss alone regardless of how much medical necessity is documented.

Uses where a UHC Medicare Advantage plan CAN cover GLP-1s (and, per CMS, must keep covering them rather than steering members to the Bridge):^[9]

• Ozempic / Mounjaro / Trulicity / Rybelsus for T2D. T2D is not a weight-loss indication, so the exclusion does not apply.
• Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, a separately FDA-approved indication since December 20, 2024.^[11] The SURMOUNT-OSA trial is the underlying evidence base.^[18]
• Wegovy for cardiovascular risk reduction in adults with established CVD and obesity or overweight.^[10]
• Wegovy for MASH — noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate-to-advanced (F2–F3) fibrosis in adults, under accelerated approval.^[10]

The Medicare GLP-1 Bridge for UHC Medicare members (since July 2026)

Separately from the Part D benefit, CMS runs a temporary demonstration, the Medicare GLP-1 Bridge, from July 1, 2026 through December 31, 2027. It is available nationwide to people with Part D coverage, including Medicare Advantage plans with drug coverage, standalone Part D plans, Special Needs Plans, and employer group waiver plans.^[8][9]

• Drugs and cost: Foundayo, Wegovy (injection or tablet), and Zepbound KwikPen only (not Zepbound vials or single-dose pens), at a $50 copayment for a month’s supply.^[8]
• Eligibility at the start of therapy: age 18+ and a BMI of 35 or higher; or BMI 30+ with heart failure with preserved ejection fraction, uncontrolled high blood pressure, or chronic kidney disease stage 3a or higher; or BMI 27+ with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.^[8]
• Not eligible: people with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease (their Part D plan may cover a GLP-1 instead), and people already getting a GLP-1 through their Part D plan.^[8]
• How it works: the prescriber sends the prescription, completes a prior authorization when requested, and certifies that you are in a diet-and-exercise program. Approval lasts through December 31, 2027 unless you switch GLP-1s. Part D plans, UHC included, are not participants and bear no financial risk.^[8][9]

UHC Community Plan (Medicaid managed care)

UnitedHealthcare Community Plan is UHC’s Medicaid managed-care line. Coverage of weight-loss GLP-1s here is not a UHC-wide policy — it follows each state’s Medicaid program and preferred drug list. Some state contracts cover weight-loss GLP-1s with PA; others exclude weight-loss-only use entirely, mirroring the broader split across state Medicaid programs.

Plan-specific lists can differ sharply. In one example, UHC added Zepbound and generic phentermine to the preferred list for its Massachusetts Senior Care Options and One Care plans effective January 1, 2025, with PA for Zepbound and a phentermine trial required for new users, while Wegovy and Saxenda left that list (Wegovy stayed covered with PA for cardiovascular risk reduction).^[4] That notice applies only to those Massachusetts plans. Confirm your own state’s UHC Community Plan drug list before assuming coverage.

How to find out if YOUR UnitedHealthcare plan covers Wegovy or Zepbound

Four reliable ways, in order from fastest to most authoritative:

1. myuhc.com member portal → Pharmacy → drug pricing and coverage. Sign in, select your plan, and search for “Wegovy,” “Zepbound,” or “Foundayo.” The result shows the tier and whether prior authorization is required for your specific plan.
2. Ask HR or your benefits administrator the AOM question directly. Because weight-loss-drug coverage is an employer election, the fastest definitive answer is often: “Does our pharmacy benefit include anti-obesity medications?” If the answer is no, no weight-loss PA will succeed.
3. Phone the member number on your card. Ask specifically: “Is (drug name) a covered benefit on my plan for chronic weight management? What is the copay tier and the PA requirement, and is there a step-therapy rule?”
4. Request the Summary Plan Description (SPD) or Evidence of Coverage (EOC). The SPD/EOC is the legal contract describing exactly what is covered. AOM exclusions, if present, are listed in the excluded-benefits section.

Prior authorization process at UnitedHealthcare (via Optum Rx)

When AOMs are a covered benefit, the PA flow runs through Optum Rx:

1. The prescriber checks the patient against UHC’s weight-loss PA criteria (BMI ≥30, or ≥27 with a weight-related comorbidity, used alongside lifestyle modification).^[3]
2. The prescriber submits the PA electronically or through the provider portal. For T2D GLP-1s the diabetes criteria apply instead.
3. Optum Rx adjudicates. At health systems connected to its PreCheck Prior Authorization tool, qualifying requests for select drugs, including diabetes GLP-1s, can be auto-approved in seconds; requests that cannot be automated go to a clinician for review rather than being denied.^[6]
4. If approved, the prescription fills at a retail pharmacy or via Optum Rx mail order with the plan copay. Authorization is time-limited, and continuation requires documented response.^[3]

If denied: UnitedHealthcare appeal pathway

UHC commercial members have a defined internal appeal pathway plus an external review track — but the first step is figuring out whether you are appealing a clinical PA denial or a benefit exclusion:

1. First-level internal appeal through UnitedHealthcare. The member or the prescribing physician submits a written appeal within the timeframe stated on the denial notice (commonly 180 days for commercial). UHC re-reviews with additional clinical documentation. This works for clinical PA denials; it will NOT reverse a benefit exclusion.
2. Second-level internal appeal if the first is upheld — often a different reviewer at a higher utilization-management tier.
3. External review (independent review organization). For fully insured commercial plans, after internal appeals are exhausted, members can request an external review through their state insurance regulator’s independent-review process; the IRO decision is binding on the plan.
4. If covered through an ERISA self-funded employer plan (the majority of UHC’s commercial book), appeals follow ERISA’s federal framework and ultimately the U.S. Department of Labor. ERISA appeals can challenge a clinical denial, but a clean benefit exclusion is a contract term, not an appealable medical-necessity decision.

For a broader view of how coverage works across payers, see our Kaiser Permanente coverage review and our insurance hub.

If UHC denies or excludes — what actually works

Ranked by cost, the practical alternatives while you appeal or if your plan permanently excludes AOMs:

• Confirm exclusion vs denial first. If it is a clinical PA denial, fix the documentation and resubmit — that is the cheapest fix of all. If it is a benefit exclusion, the appeal route is a dead end and you go straight to the options below.
• Pursue a covered non-weight-loss indication. If you have moderate-to-severe OSA, your prescriber can request Zepbound for the OSA indication; with established CVD plus overweight or obesity, or with MASH and F2–F3 fibrosis, a Wegovy request for those indications uses the same logic. UHC has separate criteria for these uses on plans that exclude weight-loss drugs.^[3][10][11]
• Medicare members: the GLP-1 Bridge. If you have Part D coverage and meet CMS’s criteria, Wegovy, Zepbound KwikPen, or Foundayo cost $50 a month through December 31, 2027.^[8]
• Manufacturer self-pay. LillyDirect Zepbound runs $299 (2.5 mg), $399 (5 mg), and $449 (7.5–15 mg when refilled within 45 days; otherwise $499–$699).^[14] Novo Nordisk lists the Wegovy pill from $149 a month, Wegovy pens at $349 (with a $199 introductory price for the first two fills through December 31, 2026), and Wegovy HD 7.2 mg at $399.^[15]
• Compounded tirzepatide or semaglutide via 503A telehealth. These are not brand Wegovy or Zepbound, prices vary widely, and quality and supply-chain rigor vary too. Diligence matters.
• Add AOM coverage or switch plans at open enrollment. If your UHC plan permanently excludes AOMs, ask HR whether anti-obesity-medication coverage can be added at renewal, or compare plans at the next open-enrollment window. For provider-side self-pay and telehealth options, see our best semaglutide providers and best tirzepatide providers rankings.

For the underlying weight-loss magnitudes (STEP 1 semaglutide −14.9% body weight at 68 weeks^[16]; SURMOUNT-1 tirzepatide 15 mg −20.9% at 72 weeks^[17]), plus drug-specific reference data, see our semaglutide drug page and tirzepatide drug page. For the broader payer landscape, see our insurance hub.

Verdict — what most UnitedHealthcare members should expect

For the median UnitedHealthcare member asking does UnitedHealthcare cover weight loss drugs: the answer is not a single national yes-or-no. It splits cleanly by indication and by who designed the benefit:

1. T2D GLP-1s (Ozempic, Mounjaro, Trulicity, Rybelsus, liraglutide): generally YES on the commercial drug list, with PA and quantity limits.
2. Chronic-weight-management GLP-1s (Wegovy, Zepbound, Foundayo, Saxenda) on a UHC commercial plan: only if your employer elected AOM coverage, which UHC says most plans do not. If yes, UHC covers them with PA. Confirm with HR and check your drug list at myuhc.com.
3. UHC Medicare Advantage members: NO for weight-loss-only under the plan; coverable for Zepbound OSA and Wegovy CV or MASH (with PA); and the CMS Medicare GLP-1 Bridge at $50 a month for eligible members.
4. UHC Community Plan (Medicaid) members: follows your state’s Medicaid drug list — varies by state; T2D and OSA/CV indications are the most reliably covered.

The single most important thing to understand about UnitedHealthcare specifically is that the employer’s election usually matters more than UHC’s own clinical policy. A clean BMI and three comorbidities will not get a weight-loss GLP-1 approved on a plan that does not cover the drug class. Diagnose the exclusion-vs-denial question first; everything else follows from that.

Further reading

• Does Kaiser Permanente cover weight-loss drugs?
• Best semaglutide providers
• Best tirzepatide providers
• GLP-1 insurance & coverage hub